These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38626524)

  • 1. Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer.
    Yang Y; Lv G; Xiu R; Yang H; Wang W; Yu P; Zhang J; Ye L; Wang H; Tian J
    Eur J Med Chem; 2024 May; 271():116400. PubMed ID: 38626524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
    Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
    Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
    Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
    Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
    Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
    Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
    Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel biphenyl derivatives as androgen receptor degraders for the treatment of enzalutamide-resistant prostate cancer.
    Zhang W; Fan Y; Zhang Y; Feng Y; Luo Y; Zhou X; Chen Z; Wang C; Lu T; Tang F; Chen Y; Li H; Jiao Y
    Bioorg Chem; 2024 Jul; 148():107433. PubMed ID: 38754311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
    Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
    Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
    Chen H; Zhang J; Hu P; Qian Y; Li J; Shen J
    Bioorg Med Chem; 2019 Oct; 27(20):115081. PubMed ID: 31493989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
    Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
    Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
    Han X; Wang C; Qin C; Xiang W; Fernandez-Salas E; Yang CY; Wang M; Zhao L; Xu T; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
    J Med Chem; 2019 Jan; 62(2):941-964. PubMed ID: 30629437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of thiohydantoin based antagonists of androgen receptor with efficient degradation for the treatment of prostate cancer.
    Chang X; Zhang D; Qu F; Xie Y; Chen T; Zhang Y; Du Q; Bian J; Li Z; Wang J; Xu X
    Eur J Med Chem; 2023 Sep; 257():115490. PubMed ID: 37209451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
    Xu X; Du Q; Meng Y; Li Z; Wu H; Li Y; Zhao Z; Ge R; Lu X; Xue S; Chen X; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2020 Apr; 192():112196. PubMed ID: 32169785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
    Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
    Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
    Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
    Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
    He Y; Hwang DJ; Ponnusamy S; Thiyagarajan T; Mohler ML; Narayanan R; Miller DD
    J Med Chem; 2021 Aug; 64(15):11045-11062. PubMed ID: 34269581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.
    Li H; Ban F; Dalal K; Leblanc E; Frewin K; Ma D; Adomat H; Rennie PS; Cherkasov A
    J Med Chem; 2014 Aug; 57(15):6458-67. PubMed ID: 25062331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.
    Sun H; Mediwala SN; Szafran AT; Mancini MA; Marcelli M
    Horm Cancer; 2016 Jun; 7(3):196-210. PubMed ID: 26957440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.